A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

Abali H., Yalcin S., Onal H. C., Dane F., Oksuzoglu B., Ozdemir N., ...More

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 21 - 23 January 2016, vol.34, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 34
  • Doi Number: 10.1200/jco.2016.34.4_suppl.tps182
  • City: San-Francisco
  • Country: Costa Rica
  • Hacettepe University Affiliated: Yes